Acticor Biotech's share price continued to soar on the Paris Bourse on Wednesday, the day after the biopharmaceutical company presented positive results for stroke treatment.

At 4.30pm, the share price had jumped by over 17%, making it yet another one of the Paris market's strongest gains in persistently high volumes.

The stock had already soared by almost 40% yesterday following the publication in the journal 'The Lancet Neurology' of promising results from the Phase 1b/2a study, which had been presented for the first time at the European Stroke Organisation (ESOC) conference in 2022.

This sudden upward movement is somewhat unexpected, given that the main results presented in the article were already known, but their appearance in a publication as prestigious as The Lancet Neurology reinforces the market's confidence in the therapeutic potential of Acticor's drug candidate", commented Jamila El Bougrini, healthcare and biotech analyst at Invest Securities.

The stock has been suffering from a lack of newsflow recently, and these data are a welcome boost, confirming that there is indeed potential in the emergency treatment of stroke, where there is a significant medical need", adds the analyst.

More and more often, clinical results that have already been unveiled are being hailed when they are published in scientific journals, as a further scientific and medical validation of their clinical proof-of-concept," she observes.

The analyst adds: "It is important to note that these strong price increases, often observed during media campaigns aimed at highlighting the positive clinical results already obtained, are the occasion for fund-raising".

"In the case of Acticor, we know that current cash resources are sufficient to cover needs until June 2024, and that a fund-raising of at least 4.5 million euros is due to be launched during the 1st quarter of this year", points out Jamila El Bougrini.

Yesterday's announcement, and the resulting sharp rise in the share price, offers them a good window of opportunity to launch a fund-raising campaign", concludes the biotech specialist.

In a study published at the beginning of the week, Invest Securities recalled that the cardiovascular field remains a highly prized subject for 'big pharmas', adding that good Phase II/III results could potentially
pave the way for Acticor to enter into discussions with potential partners.

Copyright (c) 2024 CercleFinance.com. All rights reserved.